0001209191-15-085940.txt : 20151217 0001209191-15-085940.hdr.sgml : 20151217 20151217193217 ACCESSION NUMBER: 0001209191-15-085940 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151215 FILED AS OF DATE: 20151217 DATE AS OF CHANGE: 20151217 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kite Pharma, Inc. CENTRAL INDEX KEY: 0001510580 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 BUSINESS PHONE: (310) 824-9999 MAIL ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sproule Rizwana F CENTRAL INDEX KEY: 0001609644 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36508 FILM NUMBER: 151294974 MAIL ADDRESS: STREET 1: 2225 COLORADO AVENUE CITY: SANTA MONICA STATE: CA ZIP: 90404 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-12-15 0 0001510580 Kite Pharma, Inc. KITE 0001609644 Sproule Rizwana F C/O KITE PHARMA, INC. 2225 COLORADO AVENUE SANTA MONICA CA 90404 0 1 0 0 VP Regulatory Affairs Common Stock 2015-12-15 4 M 0 9567 1.35 A 12508 D Common Stock 2015-12-15 4 S 0 3373 62.70 D 9135 D Common Stock 2015-12-15 4 S 0 2410 63.73 D 6725 D Common Stock 2015-12-15 4 S 0 3352 64.64 D 3373 D Common Stock 2015-12-15 4 S 0 432 65.38 D 2941 D Employee Stock Option (Right to Buy) 1.35 2015-12-15 4 M 0 9567 0.00 D 2024-03-24 Common Stock 9567 123464 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.17 to $63.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.17 to $64.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.24 to $65.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.24 to $65.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the 200,000 shares subject to the stock option vested and became exercisable on January 6, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. /s/ Dave Tanen, Attorney-in-Fact 2015-12-15